Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Sage Therapeutics Inc Common Stock (SAGE).
- Disclosed ownership: 7.9%.
- Date of event: 31 Dec 2024.
VANGUARD GROUP INC - 31 Dec 2024 SCHEDULE 13G/A Report for Sage Therapeutics Inc Common Stock (SAGE)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Sage Therapeutics Inc Common Stock
- Symbol
- SAGE
- Shares outstanding
- 61,242,646 shares
- Disclosed Ownership
- 4,838,169 shares
- Ownership
- 7.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 31 Jan 2025, 09:55:44 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 29 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 7.9% ownership in Sage Therapeutics Inc Common Stock (SAGE) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Jan 2025, 09:55.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 7.9% | 4,838,169 | 0 | 37,104 | Ashley Grim | Head of Global Fund Administration |